初诊时常规磁共振成像能否预测骨肉瘤的化疗耐药性?
本研究回顾性分析95例骨肉瘤患者新辅助化疗前的基线MRI,由2名骨肌放射科医生评估肿瘤特征,以手术标本组织学坏死为参考标准。约三分之二患者为化疗耐药(组织学坏死<90%)。肿瘤体积>150 mL、最大轴径>7.0 cm、坏死面积>50%、存在关节内侵犯及瘤周软组织水肿>6.5 cm显著预测化疗耐药,尤其联合出现时;肿瘤体积>150 mL和最大轴径>7.0 cm可作为独立预测因子。基线MRI表现有助于预测骨肉瘤化疗耐药,肿瘤大小是最强预测因子。
要点
- 肿瘤体积>150 mL和最大轴径>7.0 cm是新辅助化疗耐药的独立预测因子。
- 坏死面积>50%、关节内侵犯及瘤周软组织水肿>6.5 cm也显著预测化疗耐药。
- 多项征象联合出现时对化疗耐药的预测价值更高。
核心结论
- 基线MRI表现可帮助预测骨肉瘤化疗耐药,肿瘤大小是最强预测因子。
研究设计与样本
- 回顾性研究,纳入2008-2021年间95例患者,由2名骨肌放射科医生审阅新辅助化疗前的基线MRI,以手术标本组织学坏死为参考标准。
关键影像表现/征象
- 评估的MRI特征包括肿瘤体积、最大轴径、中央坏死、出血、液-液平面、瘤周骨与软组织水肿、关节内侵犯、骨骺受累、神经血管侵犯、病理性骨折和跳跃转移。
- 肿瘤体积>150 mL、最大轴径>7.0 cm、坏死面积>50%、存在关节内侵犯及瘤周软组织水肿>6.5 cm显著预测化疗耐药。
- 上述征象联合出现时预测化疗耐药的价值更高。
诊断标准与关键数值
- 化疗耐药定义为组织学坏死<90%,约三分之二患者符合。
- 肿瘤体积>150 mL和最大轴径>7.0 cm在多变量分析中为独立预测因子(P值分别为.025和.045)。
- 截断阈值由受试者工作特征曲线生成,并检验诊断准确性。
临床应用与阅片要点
- 阅片时可关注肿瘤体积、最大轴径、坏死面积、关节内侵犯及瘤周软组织水肿范围,以提示化疗耐药风险。
- 肿瘤体积>150 mL和最大轴径>7.0 cm可作为独立预测指标。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Histological tumour necrosis is the current indicator for the response of osteosarcoma after neoadjuvant chemotherapy. Chemoresistant tumours require close monitoring and adjustment of treatment. Characteristics of tumours on baseline MRI may be able to predict response to chemotherapy. The aim is to identify which baseline MRI findings can help predict chemoresistant osteosarcoma.
METHODS: Baseline MRI before giving neoadjuvant chemotherapy of 95 patients during 2008-2021 was reviewed by 2 musculoskeletal radiologists. Histological necrosis from surgical specimens was the reference standard. MRIs were reviewed for tumour characteristics (tumour volume, maximum axial diameter, central necrosis, haemorrhage, fluid-fluid level), peritumoural bone and soft tissue oedema, and other parameters including intra-articular extension, epiphyseal involvement, neurovascular involvement, pathologic fracture, and skip metastasis. The cut-off thresholds were generated by receiver operating characteristic curves which then tested for diagnostic accuracy.
RESULTS: Two-third of patients were chemoresistance (histological necrosis <90%). Tumour volume >150 mL, maximum axial diameter >7.0 cm, area of necrosis >50%, presence of intra-articular extension, and peritumoural soft tissue oedema >6.5 cm significantly predicted chemoresistance, particularly when found in combination. Tumour volume >150 mL and maximum axial diameter >7.0 cm could be used as an independent predictor (multivariable analysis, P-value = .025, .045).
CONCLUSIONS: Findings on baseline MRI could help predicting chemoresistant osteosarcoma with tumour size being the strongest predictor.
ADVANCES IN KNOWLEDGE: Osteosarcomas with large size, large cross-sectional diameter, large area of necrosis, presence of intra-articular extension, and extensive peritumoural soft tissue oedema were most likely to have a poor response to neoadjuvant chemotherapy.
引用
- Kanthawang T, Wudhikulprapan W, Phinyo P, et al. Can conventional magnetic resonance imaging at presentation predict chemoresistance in osteosarcoma? Br J Radiol. 2024. PMID: 38308035. doi:10.1093/bjr/tqad047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。